Status:
UNKNOWN
Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
Bayer
Conditions:
HCC
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Non-invasive MRI subclassification of Heptocellular Carcinoma - HepCaSt-Study
Detailed Description
Hepatocellular carcinomas (HCCs) are a heterogeneous group of tumor subtypes with a different response behavior and prognosis. As a reaction, the World Health Organization (WHO) in its 5th version (up...
Eligibility Criteria
Inclusion
- Patients with hisopathologically confirmed HCC and MRI in domo with the standard high-end MRI Primovist study protocol.
Exclusion
- Unmet inclusion criteria. MRI contraindications. Patients declines.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05202015
Start Date
January 1 2022
End Date
July 1 2024
Last Update
January 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité - University Medicine Berlin
Berlin, Germany, 13353